About this trial
Based on inclusion and exclusion criteria, this experiment plans to include 924 Heart Failure with Preserved Ejection Fraction(HFpEF) patients with increased risk of all-cause death. The enrolled patients will divided into usual care group (n=462) and targeted intervention group (n=462) in a 1:1 ratio. The usual care patients will receive routine heart failure treatment. Patients in targeted intervention group, on top of routine therapy for heart failure, will receive further therapy targeting therapy to correct hypoalbuminemia, anemia or hyponatremia, and try to enhance medication to lower N-terminal pro brain natriuretic peptide (NT-proBNP), C-reactive protein(CRP), New York Heart Association(NYHA )Classification, to add diuretics for patients with higher right ventricular diameters(RADs),multidiscipline intervention for patients complicating chronic obstructive pulmonary disease(COPD), and actively reperfusion for ischemic HFpEF patients. The incidence of all-cause death will be compared after 3 years follow-up.The primary endpoint is the occurrence of all-cause mortality events during the follow-up period.
Eligibility criteria
Qualifiers
Discharged HFpEF patients with risk score > or equal 200.37.
Disqualifiers
Patients with a life expectancy of less than 1-year due to malignancy.
Trial design
Treatments tested in this trial
- Targeted intervention based on risk factors
Treatment groups
Locations
Sponsors and collaborators
Xiangtan Central Hospital
Lead sponsor
The First People's Hospital of Xiangtan City
Collaborator
The Xiangtan People's Hospital
Collaborator
The Xiangxiang People's Hospital
Collaborator